InCa

Bührmann, M., S. Kallepu, J. D. Warmuth, J. N. Wiese, C. Ehrt, H. Vatheuer, W. Hiller, C. Seitz, L. Levy, P. Czodrowski, S. Sievers, M. P. Müller, and D. Rauh (2023). "Fragtory: Pharmacophore-Focused Design, Synthesis, and Evaluation of an sp3-Enriched Fragment Library." J Med Chem 66(9): 6297–6314. InCa  doi.org/10.1021/acs.jmedchem.3c00187.

Grabe, T., K. Jeyakumar, J. Niggenaber, T. Schulz, S. Koska, S. Kleinbölting, M. E. Beck, M. P. Müller, and D. Rauh (2023). "Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines." ACS Med Chem Lett 2023. InCa & SMOOSE  doi.org/10.1021/acsmedchemlett.2c00514.

Malchers, F., L. Nogova, M. H. A. van Attekum, L. Maas, J. Brägelmann, C. Bartenhagen, L. Girard, G. Bosco, I. Dahmen, S. Michels, C. E. Weeden, A. H. Scheel, L. Meder, K. Golfmann, P. Schuldt, J. Siemanowski, J. Rehker, S. Merkelbach-Bruse, R. Menon, O. Gautschi, J. M. Heuckmann, E. Brambilla, M.-L. Asselin-Labat, T. Persigehl, J. D. Minna, H. Walczak, R. T. Ullrich, M. Fischer, H. C. Reinhardt, J. Wolf, R. Büttner, M. Peifer, J. George, and R. K. Thomas (2023). "Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer." J. Clin. Invest. 133(21). SMOOSE & InCa  doi.org/10.1172/JCI170217.

Müller, N., C. Lorenz, J. Ostendorp, F. S. Heisel, U. P. Friese, M. Cartolano, D. Plenker, H. L. Tumbrink, A. Heimsoeth, P. Baedeker, S. Ortiz-Cuaran, J. Weiss, R. Büttner, M. Peifer, R. K. Thomas, M. L. Sos, J. Berg, and J. Brägelmann (2023). "Characterizing evolutionary dynamics reveals strategies to exhaust the spectrum of subclonal resistance in EGFR-mutant lung cancer." Cancer Res. SMOOSE & InCa  doi.org/10.1158/0008-5472.CAN-22-2605.

Guo, C., R. Wan, Y. He, S.-H. Lin, J. Cao, Y. Qiu, T. Zhang, Q. Zhao, Y. Niu, Y. Jin, H.-Y. Huang, X. Wang, L. Tan, R. K. Thomas, H. Zhang, L. Chen, K.-K. Wong, L. Hu, and H. Ji (2022). "Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer." Nature Cancer 3(5): 614-628. doi.org/10.1038/s43018-022-00358-1.

Lategahn, J., H. L. Tumbrink, C. Schultz-Fademrecht, A. Heimsoeth, L. Werr, J. Niggenaber, M. Keul, F. Parmaksiz, M. Baumann, S. Menninger, E. Zent, I. Landel, J. Weisner, K. Jeyakumar, L. Heyden, N. Russ, F. Müller, C. Lorenz, J. Brägelmann, I. Spille, T. Grabe, M. P. Müller, J. M. Heuckmann, B. M. Klebl, P. Nussbaumer, M. L. Sos, and D. Rauh (2022). "Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors." Journal of Medicinal Chemistry 65(9): 6643-6655. doi.org/10.1021/acs.jmedchem.1c02080.

Montinaro, A., I. Areso Zubiaur, J. Saggau, A. L. Kretz, R. M. M. Ferreira, O. Hassan, E. Kitzig, I. Muller, M. A. El-Bahrawy, S. von Karstedt, D. Kulms, G. Liccardi, J. Lemke, and H. Walczak (2022). "Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers." Cell Death Differ 29(3): 492-503. doi.org/10.1038/s41418-021-00869-x.

Müller, F., J. K. M. Lim, C. M. Bebber, E. Seidel, S. Tishina, A. Dahlhaus, J. Stroh, J. Beck, F. I. Yapici, K. Nakayama, L. Torres Fernández, J. Brägelmann, G. Leprivier, and S. von Karstedt (2022). "Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation." Cell Death Differ: 1–15. doi.org/10.1038/s41418-022-01096-8.

Palei, S., J. Weisner, M. Vogt, R. Gontla, B. Buchmuller, C. Ehrt, T. Grabe, S. Kleinbölting, M. Müller, G. H. Clever, D. Rauh, and D. Summerer (2022). "A high-throughput effector screen identifies a novel small molecule scaffold for inhibition of ten-eleven translocation dioxygenase 2." RSC Med Chem. doi.org/10.1039/D2MD00186A.

Pindzola, G. M., R. Razzaghi, R. N. Tavory, H. T. Nguyen, V. M. Morris, M. Li, S. Agarwal, B. Huang, T. Okada, H. C. Reinhardt, G. Knittel, H. Kashkar, R. M. Young, S. Pittaluga, and J. R. Muppidi (2022). "Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma." Blood. doi.org/10.1182/blood.2022015926.

Ratz, L., C. Brambillasca, L. Bartke, M. A. Huetzen, J. Goergens, O. Leidecker, R. D. Jachimowicz, M. van de Ven, N. Proost, B. Siteur, R. de Korte-Grimmerink, P. Bouwman, E. M. Pulver, R. de Bruijn, J. Isensee, T. Hucho, G. Pandey, M. van Lohuizen, P. Mallmann, H. C. Reinhardt, J. Jonkers, and J. Puppe (2022). "Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer." Breast Cancer Research 24(1): 41. doi.org/10.1186/s13058-022-01534-y.

Seidel, E., and S. von Karstedt (2022). "Extrinsic cell death pathway plasticity: a driver of clonal evolution in cancer?" Cell Death Discovery 8(465): 1–6. doi.org/10.1038/s41420-022-01251-7.

Werr, L., D. Plenker, M. A. Dammert, C. Lorenz, J. Brägelmann, H. L. Tumbrink, S. Klein, A. Schmitt, R. Büttner, T. Persigehl, K. M. Shokat, F. T. Wunderlich, A. M. Schram, M. Peifer, M. L. Sos, H. C. Reinhardt, and R. K. Thomas (2022). "CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization." Mol Cancer Ther 21(5): 821–830. doi.org/10.1158/1535-7163.MCT-21-0820.

Yamada, Y., D. Belharazem-Vitacolonnna, H. Bohnenberger, C. Weiß, N. Matsui, M. Kriegsmann, K. Kriegsmann, P. Sinn, K. Simon-Keller, G. Hamilton, T. Graeter, G. Preissler, G. Ott, S. Schölch, N. Nakajima, A. Yoshizawa, H. Haga, H. Date, R. K. Thomas, I. Petrini, G. Giaccone, P. Ströbel, and A. Marx (2022). "Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities." Cell Death Dis 13(979): 1–11. doi.org/10.1038/s41419-022-05428-x.

Bebber, C. M., E. S. Thomas, J. Stroh, Z. Chen, A. Androulidaki, A. Schmitt, M. N. Höhne, L. Stüker, C. de Pádua Alves, A. Khonsari, M. A. Dammert, F. Parmaksiz, H. L. Tumbrink, F. Beleggia, M. L. Sos, J. Riemer, J. George, S. Brodesser, R. K. Thomas, H. C. Reinhardt and S. von Karstedt (2021). "Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes." Nat Commun 12(2048): 1–19. InCa doi.org/10.1038/s41467-021-22336-4.

Bebber, C. M. and S. von Karstedt (2021). "Non-neuroendocrine differentiation generates a ferroptosis-prone lipidome in small cell lung cancer (SCLC)." Molecular & Cellular Oncology 8(4): 1933871. InCa doi.org/10.1080/23723556.2021.1933871.

Biagi, C. A. O., S. S. Cury, C. P. Alves, N. Rabhi, W. A. Silva, S. R. Farmer, R. F. Carvalho and M. L. Batista (2021). "Multidimensional Single-Nuclei RNA-Seq Reconstruction of Adipose Tissue Reveals Adipocyte Plasticity Underlying Thermogenic Response." Cells 10(11): 3073. InCa doi.org/10.3390/cells10113073.

Bragelmann, J., C. Lorenz, S. Borchmann, K. Nishii, J. Wegner, L. Meder, J. Ostendorp, D. F. Ast, A. Heimsoeth, T. Nakasuka, A. Hirabae, S. Okawa, M. A. Dammert, D. Plenker, S. Klein, P. Lohneis, J. Gu, L. K. Godfrey, J. Forster, M. Trajkovic-Arsic, T. Zillinger, M. Haarmann, A. Quaas, S. Lennartz, M. Schmiel, J. D'Rozario, E. S. Thomas, H. Li, C. A. Schmitt, J. George, R. K. Thomas, S. von Karstedt, G. Hartmann, R. Buttner, R. T. Ullrich, J. T. Siveke, K. Ohashi, M. Schlee and M. L. Sos (2021). "MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I." Nat Commun 12(1): 5505. InCa doi.org/10.1038/s41467-021-25728-8.

Chen, M., R. Chen, Y. Jin, J. Li, X. Hu, J. Zhang, J. Fujimoto, S. M. Hubert, C. M. Gay, B. Zhu, Y. Tian, N. McGranahan, W.-C. Lee, J. George, X. Hu, Y. Chen, M. Wu, C. Behrens, C.-W. Chow, H. H. N. Pham, J. Fukuoka, J. Wu, E. R. Parra, L. D. Little, C. Gumbs, X. Song, C.-J. Wu, L. Diao, Q. Wang, R. Cardnell, J. Zhang, J. Wang, X. Le, D. L. Gibbons, J. V. Heymach, J. Jack Lee, W. N. William, C. Cheng, B. Glisson, I. Wistuba, P. Andrew Futreal, R. K. Thomas, A. Reuben, L. A. Byers and J. Zhang (2021). "Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer." Nat Commun 12(6655): 1–13. InCa doi.org/10.1038/s41467-021-26821-8.

Quambusch, L., L. Depta, I. Landel, M. Lubeck, T. Kirschner, J. Nabert, N. Uhlenbrock, J. Weisner, M. Kostka, L. M. Levy, C. Schultz-Fademrecht, F. Glanemann, K. Althoff, M. P. Muller, J. T. Siveke and D. Rauh (2021). "Cellular model system to dissect the isoform-selectivity of Akt inhibitors." Nat Commun 12(1): 5297. InCa www.ncbi.nlm.nih.gov/pubmed/34489430.

Rosswog, C., C. Bartenhagen, A. Welte, Y. Kahlert, N. Hemstedt, W. Lorenz, M. Cartolano, S. Ackermann, S. Perner, W. Vogel, J. Altmüller, P. Nürnberg, F. Hertwig, G. Göhring, E. Lilienweiss, A. M. Stütz, J. O. Korbel, R. K. Thomas, M. Peifer and M. Fischer (2021). "Chromothripsis followed by circular recombination drives oncogene amplification in human cancer." Nat Genet 53: 1673–1685. SMOOSE, SysMED-NB & InCa doi.org/10.1038/s41588-021-00951-7.

Schaufler, D., D. F. Ast, H. L. Tumbrink, N. Abedpour, L. Maas, A. E. Schwabe, I. Spille, S. Lennartz, J. Fassunke, M. Aldea, B. Besse, D. Planchard, L. Nogova, S. Michels, C. Kobe, T. Persigehl, T. Westphal, S. Koleczko, R. Fischer, J. P. Weber, J. Altmuller, R. K. Thomas, S. Merkelbach-Bruse, O. Gautschi, L. Mezquita, R. Buttner, J. Wolf, M. Peifer, J. Bragelmann, M. Scheffler and M. L. Sos (2021). "Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer." Npj Precision Oncology 5(1). InCa doi.org/10.1038/s41698-021-00241-9.

Cartolano, M., N. Abedpour, V. Achter, T.-P. Yang, S. Ackermann, M. Fischer, and M. Peifer (2020). "CaMuS: simultaneous fitting and de novo imputation of cancer mutational signature." Sci Rep 10(19316): 1–10. doi.org/10.1038/s41598-020-75753-8.

Clemente, L. P., M. Rabenau, S. Tang, J. Stanka, E. Cors, J. Stroh, C. Culmsee, and S. von Karstedt (2020). "Dynasore Blocks Ferroptosis through Combined Modulation of Iron Uptake and Inhibition of Mitochondrial Respiration." Cells 9(10): 2259. doi.org/10.3390/cells9102259.

Jiao, H., L. Wachsmuth, S. Kumari, R. Schwarzer, J. Lin, R. O. Eren, A. Fisher, R. Lane, G. R. Young, G. Kassiotis, W. J. Kaiser, and M. Pasparakis (2020). "Z-nucleic-acid sensing triggers ZBP1-dependent necroptosis and inflammation." Nature: 1–5. doi.org/10.1038/s41586-020-2129-8.

Klein, S., A. Quaas, K.-W. Noh, M. Cartolano, N. Abedpour, C. Mauch, J. Quantius, H. C. Reinhardt, R. Buettner, M. Peifer, and D. Helbig (2020). "Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy." Clin Cancer Res 26(21): 5638–5645. doi.org/10.1158/1078-0432.CCR-20-1899.

Lategahn, J., J. Hardick, T. Grabe, J. Niggenaber, K. Jeyakumar, M. Keul, H. L. Tumbrink, C. Becker, L. Hodson, T. Kirschner, P. Klövekorn, J. Ketzer, M. Baumann, S. Terheyden, A. Unger, J. Weisner, M. P. Müller, W. A. L. van Otterlo, S. Bauer, and D. Rauh (2020). "Targeting Her2-insYVMA with Covalent Inhibitors—A Focused Compound Screening and Structure-Based Design Approach." J Med Chem 63(20): 11725–11755. doi.org/10.1021/acs.jmedchem.0c00870.

Schwarzer, R., L. Laurien, and M. Pasparakis (2020). "New insights into the regulation of apoptosis, necroptosis, and pyroptosis by receptor interacting protein kinase 1 and caspase-8." Curr Opin Cell Biol 63: 186--193. www.sciencedirect.com/science/article/pii/S0955067420300272.

Tumbrink, H. L., A. Heimsoeth, and M. L. Sos (2020). "The next tier of EGFR resistance mutations in lung cancer." Oncogene: 1–11. doi.org/10.1038/s41388-020-01510-w.

von Karstedt, S., and H. Walczak (2020). "An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer." Cell Death Discovery 6(14): 1–8. doi.org/10.1038/s41420-020-0249-4.

Quambusch, L., I. Landel, L. Depta, J. Weisner, N. Uhlenbrock, M. P. Muller, F. Glanemann, K. Althoff, J. T. Siveke, and D. Rauh (2019). "Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity." Angewandte Chemie-International Edition 58(52): 18823-18829. www.ncbi.nlm.nih.gov/pubmed/31584233.